- Home
- IMUX vs KNDI Comparison
IMUX vs KNDI Comparison
Compare IMUX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- KNDI
- Stock Information
- Founded
- IMUX 2016
- KNDI 2002
- Country
- IMUX United States
- KNDI China
- Employees
- IMUX N/A
- KNDI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- IMUX Health Care
- KNDI Consumer Discretionary
- Exchange
- IMUX Nasdaq
- KNDI Nasdaq
- Market Cap
- IMUX 67.8M
- KNDI 96.3M
- IPO Year
- IMUX N/A
- KNDI N/A
- Fundamental
- Price
- IMUX $0.73
- KNDI $1.13
- Analyst Decision
- IMUX Strong Buy
- KNDI
- Analyst Count
- IMUX 6
- KNDI 0
- Target Price
- IMUX $11.60
- KNDI N/A
- AVG Volume (30 Days)
- IMUX 2.5M
- KNDI 97.2K
- Earning Date
- IMUX 08-07-2025
- KNDI 08-15-2025
- Dividend Yield
- IMUX N/A
- KNDI N/A
- EPS Growth
- IMUX N/A
- KNDI N/A
- EPS
- IMUX N/A
- KNDI N/A
- Revenue
- IMUX N/A
- KNDI $127,569,613.00
- Revenue This Year
- IMUX N/A
- KNDI N/A
- Revenue Next Year
- IMUX N/A
- KNDI N/A
- P/E Ratio
- IMUX N/A
- KNDI N/A
- Revenue Growth
- IMUX N/A
- KNDI 3.21
- 52 Week Low
- IMUX $0.56
- KNDI $0.89
- 52 Week High
- IMUX $2.11
- KNDI $2.12
- Technical
- Relative Strength Index (RSI)
- IMUX 41.54
- KNDI 48.38
- Support Level
- IMUX $0.68
- KNDI $1.06
- Resistance Level
- IMUX $0.74
- KNDI $1.16
- Average True Range (ATR)
- IMUX 0.06
- KNDI 0.07
- MACD
- IMUX 0.00
- KNDI 0.00
- Stochastic Oscillator
- IMUX 27.43
- KNDI 42.86
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.